Skip to content
10-Q

Quarterly Report

Fulgent Genetics, Inc. FLGT

0000950170-25-062258

← back to feed
Filed
May 2, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 28, 2025 30.44M sh
Stockholders Equity Q1 2025 · Mar 31, 2025 $1.13B
Stockholders Equity Q1 2025 · Dec 31, 2024 $1.13B
Current Liabilities Q1 2025 · Mar 31, 2025 $65.92M
Current Liabilities Q1 2025 · Dec 31, 2024 $72.9M
Total Liabilities Q1 2025 · Mar 31, 2025 $82.97M
Total Liabilities Q1 2025 · Dec 31, 2024 $90.81M
Current Assets Q1 2025 · Mar 31, 2025 $416.78M
Current Assets Q1 2025 · Dec 31, 2024 $353.57M
Total Assets Q1 2025 · Mar 31, 2025 $1.21B
Total Assets Q1 2025 · Dec 31, 2024 $1.22B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $55.14M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $54.68M
Shares Diluted Q1 2025 · Mar 31, 2024 29.77M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $225K
Capex Q1 2025 · Mar 31, 2024 $4.06M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $7.27M
Sga Expense Q1 2025 · Mar 31, 2024 $21.49M
Rd Expense Q1 2025 · Mar 31, 2024 $11.43M
Net Income Q1 2025 · Mar 31, 2024 −$13.46M
Operating Income Q1 2025 · Mar 31, 2024 −$21.8M
Gross Profit Q1 2025 · Mar 31, 2024 $22.1M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $42.38M
Revenue Q1 2025 · Mar 31, 2024 $64.49M